Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT) - Trial NCT06134622
Access comprehensive clinical trial information for NCT06134622 through Pure Global AI's free database. This Phase 3 trial is sponsored by The First Affiliated Hospital of University of Science and Technology of China and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 832 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital of University of Science and Technology of China
Timeline & Enrollment
Phase 3
Jan 01, 2024
Jun 30, 2027
Primary Outcome
a modified Rankin Score of 0-1
Summary
To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis
 for patients with AIS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06134622
Non-Device Trial